Glenmark Pharmaceuticals has launched the antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of mild to moderate COVID-19 cases, while Cipla and Hetero have received approvals from the Drug Controller General of India (DCGI) to launch Remdesivir under the brand names Cipremi and Covifor respectively. ET's Divya Rajagopal reports on how Remdesivir, Dexamethasone and Favipiravir are showing promising results in the fight against different coronavirus phases. (Text: PTI)
► Subscribe to The Economic Times for latest video updates. It's free! - [ Ссылка ]
► More Videos @ ETTV - [ Ссылка ]
► [ Ссылка ]
► For business news on the go, download ET app:
[ Ссылка ]
Follow ET on:
► Facebook - [ Ссылка ]
► Twitter - [ Ссылка ]
► LinkedIn - [ Ссылка ]
► Instagram - [ Ссылка ]
► Flipboard - [ Ссылка ]
